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Abstract
Background: South Africa has achieved drug-susceptible TB (DS-TB) treatment success of only 77% among people
with new and previously treated TB. Alternative approaches are required to improve medication adherence and
treatment completion to limit transmission, TB relapse and the development of resistance. This study aims to
implement and evaluate the use of adherence medication monitors (Wisepill evriMED 1000) with a differentiated
response to patient care, among DS-TB patients in three provinces of South Africa.
Methods: In total, 18 public health clinics across three provinces were selected. Clinics were randomised to intervention or
standard of care clinics. In each clinic, approximately 145 DS-TB patients are being enrolled to reach a total of 2610. All
patients have their daily adherence monitored using medication monitors. In the intervention arm, patients are receiving
medication monitor reminders and differentiated care in response to adherence data. This weekly review of daily real-time
monitoring will be undertaken from a central database. The differentiated care model includes automated SMS reminders
with a missed dose, research staff-initiated phone call to the patient with a second or third missed dose, a home visit if four
or more doses are missed, and motivational counselling if four or more doses are missed repeatedly. Fidelity of the
intervention will be measured through process evaluation. Patients in control clinics will receive medication monitors for
adherence tracking, standard of care TB education, and normal clinic follow-up procedures. The primary outcome is the
proportion of patients by arm with >80% adherence, as measured by the medication monitor. The feasibility and
acceptability of the intervention will be assessed by in-depth interviews with patients, stakeholders, and study staff. A cost
effectiveness analysis of the intervention and standard of care clinics will be conducted.
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Significance: This trial will provide evidence for the use of an intervention, including medication monitors and differentiated
care package, to improve adherence to TB treatment. Improved adherence should also improve TB treatment completion
rates, thus reducing loss to follow-up rates, and TB relapse among people with TB. The intervention is intended to ultimately
improve overall TB control and reduce TB transmission in South Africa.
Trial registration: Pan African Trial Registry PACTR201902681157721. Registered on 11 February 2019.
Keywords: Medication adherence, Tuberculosis, Medication monitor, Real-time medication monitoring
Introduction
Globally, an estimated 10 million people with TB were
identified with new and previously treated tuberculosis
(TB) in 2018 [1]. Of the 6.4 million people with TB,
who started on treatment in 2017, treatment success
was reported in 85% [1]. South Africa reported treat-
ment success rates of 77% among all people with new
and previously treated TB as well as 75% among
HIV-positive people with TB [1]. Poor medication ad-
herence contributes to lower treatment completion
among people with TB [2]. Poor medication adher-
ence also contributes to an increased rate of TB
relapse [3].
Systematic reviews show that the traditional approach
to facility-based directly observed treatment (DOT) does
not improve treatment completion, microbiological
cure, disease relapse rates, and rates of acquired drug
resistance when compared to self-administered ther-
apy [4–6]. Facility-based DOT is time-consuming, is
highly resource intensive, and creates barriers to re-
tention in care and treatment completion. It is also
inconvenient to people living with TB and results in
loss of income and employment [7, 8]. Alternative
and innovative approaches are required to improve
medication adherence and treatment completion to
limit transmission, TB relapse, and the development
of drug-resistance.
A number of digital health adherence technologies have
been explored recently including the electronic medication
monitor (as in this study), the 99-DOTs (a cardboard sleeve
which requires patients to send a short message services
[SMS] or make a missed call after taking a dose) [9], and
video-supported treatment [10] (smart phone based technol-
ogy using video to record medication intake). A cluster ran-
domised trial of 4500 TB patients in rural and urban China
showed improved medication adherence in patients rando-
mised to the medication monitor compared to SMS messa-
ging or the standard of care [11]. The medication monitor
was well accepted by patients and providers [12]. A differen-
tiated care approach, one of the pillars of the End-TB strat-
egy, defined as a client-centred approach that simplifies and
adapts services along the care cascade, may better serve the
needs of patients and reduce the burden on the health sys-
tem and has the potential to improve medication adherence
[13]. A further study to evaluate the use of medication moni-
tor, this time with real-time reporting and with differentiated
care, is being conducted in China [14]. Electronic medication
monitors have not been formally evaluated in drug-
susceptible TB (DS-TB) patients in South Africa. The use of
these electronic monitors could assist the country in reaching
the global TB plan target of 90% successfully completing
their treatment. Monitoring of the adherence data will assist
in identifying who needs more support under a differentiated
model thereby directing scarce resources to them. In this
trial, we will evaluate whether implementation of a medica-
tion monitor (smart pill box; Wisepill evriMED 1000 device),
coupled with daily monitoring and differentiated care, is able
to improve adherence and reduce poor outcomes in patients
with DS-TB treatment.
Methods
The study protocol has been reported in accordance
with the Standard Protocol Items: Recommendation for
Clinical Interventional Trials (SPIRIT) guidelines (add-
itional file 1 for details).
Study design and setting
The trial is parallel group, cluster-randomised taking
place in six clinics in each of three provinces in South
Africa: Gauteng (Ekurhuleni district), Western Cape
(Klipfontein and Mitchell’s Plain districts), and Kwa-
Zulu Natal (eThekwini district). The study is evaluating
if the intervention is superior to the control treatment.
Clusters were defined as public health clinics with at
least 200 TB registrations in 2017. Adult HIV prevalence
in the general population is 18.2% in Kwa-Zulu Natal,
12.5% in Gauteng, and 8.9% in Western Cape province
[15]. Prior to randomisation, we considered urban or
rural location of clinic, total number of patients starting
TB treatment per month, and treatment outcomes in
the last 12 months. Clusters were randomised 1:1 to
intervention or standard of care arm using restriction to
ensure that each province has at least one intervention
and one standard of care clinic [16]. Randomisation was
conducted by a computer programme (Stata) which gen-
erated all possible randomisations (48,620). Restrictions
were applied to eliminate randomisations for which fa-
cilities in the two groups were not balanced by province
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(0–1 or 5–6 facilities from each province per arm) which
left 35,000 possible options. Ten thousand of the rando-
misations were randomly selected for convenience and
listed in an Excel spreadsheet, labelled as 0000–9999.
Clinic/DOH representatives present at the randomisa-
tion meeting chose 4 golf balls (each numbered 0,1,… 9)
to select a randomisation option. Unfortunately, follow-
ing the randomisation though before participant enrol-
ment had started, two clinics, from each arm (same
province), had to withdraw due to ongoing TB studies.
These were replaced by two clinics in the same province
and were allocated to the intervention and control arm
at random.
Study population and eligibility criteria
The study is recruiting all adults aged ≥18 years and
children aged 2–17 years with clinically or microbio-
logically diagnosed DS-TB. The inclusion criteria include
initiating TB treatment within the last 14 days, adults
and caregivers of children who are willing and able to
provide informed consent, and children aged 7–17 years
old who are willing and able to provide informed assent.
Patients need to be willing to use the medication
monitor; agree to be followed-up with text messaging,
phone calls, and home visits; live within the study catch-
ment area; and be willing to inform the study team of
any change of address during the treatment as well as
follow-up period. We expect to enrol approximately
2610 DS-TB patients and follow them up for 18 months
post enrolment. The study started enrolment in May
2019 and will complete follow-up in December 2021.
This manuscript could not be submitted for consider-
ation before enrolment commenced as the methodology
had to piloted and refined during the early phases of the
enrolment period.
Description of study arms and procedures
Intervention clinics
Enrolled patients receive the differentiated care adherence
package. This includes standard patient education and
provision of medication monitor programmed to alert pa-
tients (using sound and a light on the box) on a daily basis
as a reminder to take their medication (Table 1). Patients
are educated on how to use the medication monitor by
the study team. The medication monitor transmits a daily
signal to the Wisepill system (system), referred to as






M1 M2 M3 M4 M5 M6 M9 M12 M15 M18
Informed consent √
Eligibility criteria verified √
Of those eligible:
Locator information √ √ √ √ √ √ √ √ √ √ √
Brief medical history √
Risk assessment for TB √
Economics questions √
Stigma scale √ √ √
Facility dispensed treatment √ √ √ √ √ √
Education on the medication monitor and monitor provided to patient √
Medication monitor configured to have visual and audio reminders—
intervention arm only
√
Participants’ experience using medication monitor and adherence discussion
for intervention—intervention arm only
√ √ √ √ √ √
Social harm √ (√*)
Pre-treatment, two and five months routine specimens abstracted from record √
Treatment completion history abstracted from routine records √
TB Symptom screen** √ √ √ √
Research clinic visit √ √ √ √
Sputum culture and GXP √(*) √ (√) (√) (√) √
GXP Gene Xpert MTB/Rif
(*) collect culture for those who were diagnosed via chest radiograph or clinically or have negative GXP result; **TB investigations performed if participant is
symptomatic for TB; (√) sputum collected for culture and GXP if TB symptoms are reported at that visit; (√*) only done if social harm case report form was not
completed at month 6
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heartbeat, to indicate that it is working properly. There
are also additional reminders for monthly dispensing visits
and the device uploads data in real-time to a central data-
base that allows for weekly review by research staff.
Weekly automated reports are generated from the system
that lists patients who had missed any doses and those
whose devices are not sending a signal correctly. A step-
wise approach to missed doses is then implemented that
includes phone calls, home visits, and motivational coun-
selling for those who consistently miss medication doses
(Table 2). Automated SMS reminders are sent to any pa-
tient in the intervention with a missed dose. A second or
third missed dose in a week triggers a research staff-
initiated phone call to the patient, and four or more
missed doses in a week trigger a home visit. Phone calls
and home visits are scripted. Should four or more doses
be repeatedly missed, additional adherence measures such
as motivational counselling is done. When participants
visit the clinic for their usual dispensing visit, the research
staff shows the participant their own data and discusses
their medication adherence history.
Standard of care clinics
Enrolled patients are provided with a return date for col-
lection of repeat medication in 30 days. Patients are also
provided with the medication monitor and educated on its
use by the study team (Table 1). The medication monitor
records data on box opening and is not configured to have
visual or audio reminders for intakes or refills. The medi-
cation monitor transmits a daily “heartbeat” signal to the
system to indicate that it is working properly. In contrast
to the intervention clinic patients, data collected on the
system is not reviewed during follow-up study visits. Pa-
tients receive counselling regarding their TB treatment as
per standard of care only. Neither the research staff nor
the patient accesses the medication monitor information
at follow-up study visits.
Follow-up
Follow-up of all patients in intervention and standard of
care arms continues every 3 months until 12 months
after completion of treatment (approximately 18 months
after enrolment) (Table 1). Patients who die, declared as
loss to follow-up during treatment by facility staff, or
move out of our study area will be withdrawn from
study. At each follow-up visit, TB symptom screening
will be performed and, if required additional investiga-
tions such as sputum tests, will also be conducted. Pa-
tients are reimbursed ZAR 50 for travel costs for each
visit. All patients are requested to provide sputum speci-
mens for culture testing at 6 months from enrolment
and 12 months post TB treatment completion (18
months from enrolment).
Qualitative evaluation
The feasibility and acceptability of the intervention will
be assessed by conducting at least 60 in-depth interviews
with patients who received the intervention, and at least
six stakeholders and study staff who implemented the
intervention. Patient interviews will be done post enrol-
ment across varied follow-up times to allow for variation
regarding the use of medication monitors. They will also
be selected according to their gender, age and how ad-
herent they are according to the weekly analysed adher-
ence data (adherence category). These patients will be
reimbursed R150 for their time. For feasibility of the
intervention, we will explore the following: how easy it
was to use the medication monitors, concerns about in-
advertent disclosure of TB status with having a medica-
tion monitor for medication, and how useful patients
found the SMS reminders, calls and home visits. Key
stakeholders at provincial and district level will be inter-
viewed to understand the motivators and challenges to
integrating this model of care into the current health
system and how the use of this technology could influ-
ence policy change. For acceptability, we will explore ap-
propriateness of the intervention, issues encountered,
and perceptions of benefit from both patients and
providers.
Economics evaluation
The cost-effectiveness analysis of the intervention will
entail estimating all direct and indirect costs from the
intervention and standard of care clinics. Costing will be
based on a societal perspective. All costs related to the
resources utilised in delivering the intervention such as
personnel, equipment, supplies, and training will be
gathered using a bottom-up costing approach. Personnel
costs associated with time spent conducting their daily
activities will be acquired using a survey and time and
motion methods and timesheets. Time spent on voice
calls to patients will be estimated using itemised billing
records from the service provider. Patient costs will be
estimated using a questionnaire at enrolment, 2 and 6
month’s visits, and compared in both trial arms to iden-
tify patient cost drivers. We will calculate the




Weekly doses missed Intervention
85% 1 Same day SMS reminder
(automated)
45–84 % 2 or 3 Voice call by research staff
<45% 4 or more Home visit and/or clinic visit
Greater than 1 week
with 4 or more missed
doses
Recall for other adherence
measures, e.g. motivational
counselling.
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incremental cost-effectiveness ratio for the clusters per
treatment arm.
Ethics approval
The study has ethical approval from the University of
Witwatersrand (Ref 180705) and the University of Cape
Town (Ref 452/2018), as well as, from the London
School of Hygiene & Tropical Medicine (Ref 16107). It
also has approval from the health management of the
three Provincial Offices, as well as City of Cape Town,
eThekwini and Ekurhuleni district research committees.
The study has a Trial Steering Committee that meets bi-
annually to discuss study progress. The trial steering
committee is comprised of six members and these are
the following: PI of the study, Western Cape regional PI,
National Department of Health representative, South
African-based TB expert, and two internationally based
TB experts. The steering committee is responsible for
providing expert oversight of the trial, monitoring re-
cruitment as well as follow-up rates and reviewing strat-
egies from the investigators to deal with problems,
providing recommendations as to the future continu-
ation of the trial, reviewing regular data reports of the
trial progress, and lastly approving external or early in-
ternal requests for release of data or subsets of data or
samples including clinical data and stored biological
samples. Written, informed consent is being sought from
all potential participants by study staff (research assist-
ant) before taking part in the study. Assent is also being
obtained from participants aged 7–17 years.
Trial outcomes
The primary study endpoint is medication adherence
which will be measured as the proportion of patients by
arm with >80% adherence, as measured by the medica-
tion monitor. For those lost to follow-up during treat-
ment, we will assume no drug intake (100% non-
adherence) for the period from the date of being lost to
follow-up to the date of scheduled treatment comple-
tion. Secondary endpoints will be successful outcome at
the end of treatment and unfavourable outcomes at 18
months post enrolment. Treatment success will be mea-
sured as the proportion of patients by arm that either
have a documented cure or treatment completion by
210 days following commencement of TB treatment. A
TB culture will be performed at the end of treatment to
confirm response to treatment. TB recurrence will be
determined through incident TB cases in the year fol-
lowing completion of DS-TB treatment. Unfavourable
outcome at 18 months after enrolment will include on-
treatment lost to follow up, death, treatment failure, and
treatment recurrence. Fidelity of the intervention will be
measured by reporting on percentage of patients who
were supposed to receive an SMS or phone call who did
and percentage of patients who received counselling
when required. We will also report on percentage of
boxes with failures. We will also report on percentage of
patients withdrawing from study due to refusal of using
digital adherence technology.
Qualitative outcomes will be on appropriateness and
perceptions of patients as well as providers involved with
the implementation of the intervention. We will also re-
port on reaction to use of the medication monitor as well
as the suitability of this medication monitor to participant
living conditions, the motivators of using the medication
monitor to take treatment, and challenges to integrating
the differentiated model of care into the current health
system. We will further explore differences across patients
by age, category of adherence, and location.
Economic outcomes will be based on cost per person
with >80% adherence to DS-TB treatment, cost per per-
son with TB who successfully completed DS-TB treat-
ment, proportion experiencing catastrophic costs, and
cost drivers and incremental cost-effectiveness ratio.
Study outcomes’ definitions
Treatment completed is defined as patient who has com-
pleted their treatment without evidence of failure but
without any record of a negative smear or culture result
in the last month of treatment or any time in previous
occasion.
Cured is defined as pulmonary TB patient with a posi-
tive smear, Xpert MTB/Rif or culture result (bacterio-
logically confirmed TB) at the beginning of treatment
who has a negative smear microscopy or culture result
at the last month of treatment.
Lost to follow-up is defined as a patient whose treat-
ment has been interrupted for more than 2 months.
Treatment failed is defined as a patient whose sputum
smear or culture is positive at month 5 or later during
treatment.
TB recurrence is defined as a patient with a positive
culture result at any time during the 12 months follow-
up period post treatment completion.
Unfavourable outcome at 18 months post enrolment is
defined as treatment failure, lost to follow-up and death
during treatment, and recurrence after end of treatment.
Sample size considerations
Sample size calculations were conducted accounting for
the clustered design [16]. Throughout we have assumed
a harmonic mean of 145 TB patients/cluster, nine clus-
ters per arm and a two-sided type I error of 5%.
Proportion with >80% adherence: Assuming a percent-
age with non-adherence in the standard of care arm of
30% and coefficient of variation of variation of 0.12, we
will have 90% power to detect a 40% reduction in the
endpoint in the intervention arm. For a successful
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outcome at the end of treatment of 80% in the standard
of care arm and a coefficient of variation of 0.06, we will
have 90% power to detect an increase to 90%. For un-
favourable outcome 18 months after enrolment (defined
as on-treatment lost to follow-up, death, treatment fail-
ure, and recurrence) of between 13 and 20% in the
standard of care arm and a coefficient of variation of
0.25, we will have at least 80% power to detect a 40% re-
duction in the intervention arm.
Data management and analyses
Research staff were trained to capture all data into web-
based database which is encrypted to ensure compliance
to the South Africa’s Protection of Personal Information
Act (POPI). If Internet connection is not available, a
paper-based system is implemented and data captured
into the web-based system once Internet connectivity is
restored. Documents containing personal identifiers will
be kept in lockable cabinets that are only accessible by
study staff.
The database access is restricted with an encrypted
password. All fields have automated system checks,
which verify missing, range, and future dates. Any per-
sonal identifiers will be removed from the analytic data-
set prior to the data analysis phase of the study. The
data management team carries out a centralised statis-
tical monitoring. Baseline characteristics data will sum-
marised at individual level for all participants in the two
arms. The individual data will include age, gender, ethni-
city, education, marital status, number of people they
live with, special risk factors for TB, TB history, HIV sta-
tus, antiretroviral status, CD4 count, and viral load. We
will also report on TB treatment category, sputum re-
sults, smoking, alcohol and recreational drugs use, and
TB related stigma at three time points which are at the
start of taking TB treatment, completion of TB treat-
ment, and end of 18 months follow-up. The study is also
collecting data on social harm during the course of treat-
ment at the end of TB treatment and adverse events will
be reported to the Ethics committees. To answer our
main objective, we will measure adherence using data
from the medication monitors. A box opening any time
during the day will be taken as a proxy for medication
intake. Adherence will be calculated by dividing the
number of days when pills were taken over number of
days that pills were supposed to be taken to generate an
adherence proportion for each individual enrolled. We
will then generate a binary variable for each participant
based on ≥ 80% adherence.
Analysis will be conducted at cluster-level due to the
small number of clusters [16]. For each cluster the pro-
portion of participants with ≥80% adherence is measured
and the log(proportion) compared by study arm using a
t test. We will also conduct an adjusted analysis for the
intervention effect, adjusting for imbalances of
individual-level variables at baseline, using a two-stage
approach [16]. We will fit a logistic regression model at
the individual-level including any baseline variable which
look imbalanced by study arm and variables which we
anticipate to be associated with poor adherence. The ex-
pected outcome for each individual is calculated and
summed at the cluster-level. The log of cluster-level re-
sidual (expected number of outcomes with the observed
number of outcomes) is compared by study arm using a
t test. We plan to also specify a limited number of sub-
groups and endpoint(s) they relate to. Subgroups will be
measured at the cluster-level (e.g. province) or
individual-level (e.g. sex, education, stigma-level). We
will then estimate the intervention effect in each sub-
group. A full statistical analysis plan will be developed
before study completion.
For the secondary objectives, we will generate a binary
variable indicating whether enrolled participants had
successfully completed six months of TB treatment or
not. Unfavourable outcomes will be measured by gener-
ating a binary variable indicating whether enrolled par-
ticipants had an unfavourable outcome 18 months after
enrolment.
A detailed statistical analysis plan will be written prior
to any analyses. The trial investigators will have access
to the final dataset.
For the qualitative component, audio-recordings and
process notes will be transcribed and where necessary
translated prior to analysis. Data will be analysed using
QSR NVIVO 10 qualitative analysis software and manual
reviewing. Thematic analysis using deductive and in-
ductive approaches will be used to describe the themes.
A codebook will be created using the deductive themes
and updated with any new themes that develop from the
transcripts. Saturation of themes will be assessed during
study implementation by frequent review of the tran-
scripts. For reliability, the original transcript and code-
book will be sent to two independent reviewers.
For economics evaluation, all time and motion data
will be collected onto a paper form and captured onto
an Excel workbook by trained research assistants. The
health economist will review the data on a regular basis
and clarifications requests made promptly to avoid recall
bias. Patient costing data will be collected on case report
forms and entered into a password-protected database
created in REDCap database. Data will be exported from
REDCap into STATA (version 14, StataCorp LP, College
Station, Texas) for analysis.
Discussion
The study aims to evaluate whether implementation of
medication monitors with daily remote monitoring and
differentiated care is able to increase the proportion of
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patients with ≥ 80% adherence to drug sensitive TB
treatment. Although medication monitors have been
used to measure adherence in HIV treatment patients,
this study is among the few studies investigating adher-
ence using medication monitors among drug-sensitive
TB patients in sub-Saharan Africa [17]. The study is also
one of the first to evaluate differentiated care following
information from an adherence technology. The medica-
tion monitor offers a real time documentation of medi-
cation intakes, which allows ability to monitor
medication adherence whenever required. This approach
will also allow for a further discussion of why non-
adherence occurred when participants return to facility
for refills. The differentiated care approach enables staff
to follow-up on a weekly basis on participants that have
missed doses allowing for timely action on missed doses
unlike waiting for patients to return to facilities at end
of the month as it is currently done in routine practice.
The approach will also assist us in identifying people
with TB who may need more support when on TB
treatment.
Other digital adherence technologies that have been ex-
plored for TB medication adherence include 99-DOTS,
which requires patients to give a missed call to a toll free
number when the pills are removed from the medication
blister pack when taking a dose. The disadvantage of using
99-DOTS is that treatment support before treatment in-
take is not provided but only done once a patient misses a
dose [9]. Another technology that has been explored is
video-supported treatment where patients take a video of
themselves ingesting TB treatment and sending it to
health care providers to view later [18]. The disadvantage
with using this technology is that it requires that a patient
have a smartphone and have access to Internet connec-
tion. Other criticisms have been that it is an intrusive and
patronising method. Both these technologies require some
effort from the patient to either give a missed call, send an
SMS to the toll free number for 99-DOTS, or take a video
of themselves ingesting medication. Furthermore, 99-
DOTS sleeves have to be customised to the different
medication blister packs.
The advantages of the medication monitor over the
other technologies is that it has both visual and audio
medication reminders and monthly refill reminders. The
monitor software also automatically sends text messages
to patients if a patient does not take their medication at
the scheduled time. All these features attempt to support
patients when taking treatment [19]. With differentiated
care based on adherence monitoring, one may be able to
counter issues, related to fear of side effects, lack of dis-
closure, lack of support, etc., through additional motiv-
ational counselling.
There are some operational challenges that need to
be overcome to implement the study. To implement
the intervention, staff need access to a computer/
portable device to be able to assign a device to a pa-
tient. Having a computer in the TB consultation
rooms is not the current practice in South Africa and
we will therefore provide electronic tablets loaded
with data to our study team so this can be done. The
research team is operationalising the intervention and
they require cell phones and airtime to be able to call
patients who missed their doses, these will also be
provided by the study. The configuring of each device
also requires access to an Internet connection. Most
facilities in South African do not have free Internet
access available and the study must therefore provide
data to the study team. Reports that will be used to
implement the differentiated care will not be auto-
matically generated, so a dedicated person needs to
download and generate them weekly. One of the
study staff per province will be responsible for ensur-
ing that this is done. During the follow-up period
that patients are still taking their TB treatment, we
run a risk of some patients losing their medication
monitors. If this occurs, the study will replace the
medication monitors.
Limitations
One limitation of the study is that intake notification
through opening of the box does not mean that a patient
has ingested their medication. We might get instances
where the system has recorded an opening as an intake
but the patient has not ingested the medication and vice
versa. We will not perform plasma or urine drug con-
centration tests to check objectively on dosing. However,
there is evidence in HIV patient populations in South
Africa that electronic adherence monitoring monitors
are a good measure for adherence [20].
A second limitation is that most TB patients in South
Africa have HIV co-infection but the current study is
not monitoring medication adherence for both diseases.
While the differentiated care strategy is labour intensive,
the study will allow us to evaluate which elements are
more feasible and practical and which are more effective.
The HIV community in the country is already using a
differentiated care model to address non-adherence in
patients [21]; therefore, use of this approach in TB care
might bring opportunities for integrated patient manage-
ment. We are assuming high levels of acceptability of
the medication monitor; this will be assessed in the
qualitative aspects of the study. This might also intro-
duce some population selection bias in our study as only
people that are willing to use the medication monitor
will be enrolled and not everyone with TB who are
started on TB treatment in the facilities that we are
recruiting from.
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Strengths
The strength of this study is that it is a pragmatic trial,
taking place in 18 clinics across three provinces of South
Africa reflecting rural and urban settings, with varying
TB and HIV burdens. In addition, the study is being
conducted within the routine programme and care is
likely to be influenced by the routine setting, although
research staff may support some activities. We are using
trained lay workers to educate participants about their
treatment, which is a strength, and if found to be suc-
cessful, the intervention could be implemented without
requiring specialist highly trained staff. The inclusion of
the socio-behavioural and economic evaluations will
allow implementation issues to be explored allowing for
easier implementation if the intervention is found to be
successful.
Dissemination
Our study findings will be shared with the facility man-
agers and district officials where the study took place, as
well as provincial and national Department of Health
stakeholders. The study is part of the national DISRUPT
TB Innovations Consortium in South Africa through
which results will be shared with other TB researchers,
non-governmental organisations, and provincial and na-
tional stakeholders. In addition, findings will be dissemi-
nated in both local and international conferences, and
published in peer-reviewed journals. Authorship on pub-
lications generated for this trial will be granted to indi-
viduals who have contributed substantively to the
design, conduct, and interpretation of trial findings as
well as reporting of the trial. A de-identified participant-
level dataset will also be made available after journal
publication.
Conclusions
The current study will report on the feasibility, accept-
ability, and cost-effectiveness of using remote medica-
tion monitors with a differentiated care approach to
support DS-TB patients within the South African con-
text. If this intervention is successful, a larger implemen-
tation project will be needed to further understand the
implementation challenges of rolling out the interven-
tion at a wider scale.
Trial status
The protocol is version 5.0, dated 25 February 2020. The
trial started recruitment on 17 May 2019. The recruit-
ment to trial is ongoing until December 2020 and
follow-up is expected to be completed on 30 December
2021.
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